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Background
Cancer pain is a significant clinical problem being one of
the first symptoms of disease with 75–90% of the patients
experiencing chronic pain syndromes in advanced stages
[1]. The management of cancer pain is mainly based on
the use of opioid drugs; however their clinical use is lim-
ited by high incidence of adverse effects. There is a con-
tinued search for highly efficacious opioid analgesics with
reduced complications and improved patient compliance.
An analogue of the clinically used oxymorphone,
5-methyl-substituted 14-O-methyloxymorphone (HS-
198), is a selective μ opioid agonist and a potent antinoci-
ceptive agent in animal models of nociceptive and
inflammatory pain, while exhibiting a favourable dissocia-
tion between analgesia and the occurrence of side effects
[2]. We report data on efficacy of this opioid agonist after
subcutaneous administration (s.c.) in a murine model of
cancer pain. The opioid receptor-mechanistic basis of the
antinociceptive action was also investigated.
Methods
Cancer pain was induced in C57BL/6J mice by s.c.
implantation of lung carcinoma cells, in the plantar and
dorsal side of the right hindpaw [3]. Mechanical sensi-
tivity was determined using von Frey monofilaments.
Heat sensitivity was assessed using the Hargreaves test.
In vitro biological activities were evaluated using binding
and functional assays.
Results
On day 9 post-inoculation, s.c. HS-198 produced a dose-
dependent inhibition with significant effects in attenuating
cancer pain-related behaviour (thermal and mechanical
hypersensitivity) on the tumour side. Pre-treatment with
the opioid receptor antagonist naloxone reversed the anti-
nociceptive effects induced by HS-198 in mice with can-
cer-induced pain. In vitro, HS-198 showed high affinity
and selectivity for both mouse and rat μ opioid receptors,
and it displayed potent μ-agonism through inhibition of G
proteins.
Conclusions
Systemic s.c. administration of the μ opioid receptor
agonist HS-198 induces potent antinociceptive effects in
mice with cancer pain via opioid receptor-specific
mechanisms.
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